Literature DB >> 14652823

Activating Gs alpha mutation at the Arg201 codon in liposclerosing myxofibrous tumor.

Atsushi Matsuba1, Akira Ogose, Kunihiko Tokunaga, Hiroyuki Kawashima, Tetsuo Hotta, Sayuri Urakawa, Hajime Umezu, Takeshi Higuchi, Naoto Endo.   

Abstract

Liposclerosing myxofibrous tumor (LSMFT) is a benign fibro-osseous lesion that is characterized by mixture of histologic elements including lipoma, fibroxanthoma, myxoma, ischemic ossification, and fibrous dysplasia (FD)-like features. These tissue components are seen in the original reports of FD; however, the relationship between LSMFT and FD is not clear. Point mutation of the alpha subunit of G protein (Gs alpha), which increases cyclic adenosine monophosphate formation, has been recognized as the cause of McCune-Albright syndrome as well as polyostotic and monostotic FD of bone. Gs alpha mutation at the Arg201 codon in 2 patients of LSMFT was demonstrated in the present study. Although direct sequencing analysis using the fresh-frozen materials could not detect the mutation, the polymerase chain reaction fragmentation length polymorphism (PCR-RFLP) disclosed the missense point mutation Gs alpha at the Arg201 codon in 2 cases involving LSMFT. This result strongly suggests that a subset of LSMFT is a variant form of FD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652823     DOI: 10.1016/s0046-8177(03)00430-1

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

1.  Liposclerosing myxofibrous tumor (LSMFT), a study of 33 patients: should it be a distinct entity?

Authors:  Jonathan Dattilo; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2012

2.  Case report: two-step malignant transformation of a liposclerosing myxofibrous tumor of bone.

Authors:  Kirk Campbell; Felasfa Wodajo
Journal:  Clin Orthop Relat Res       Date:  2008-07-08       Impact factor: 4.176

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.